In a letter to HHS Secretary Robert F. Kennedy Jr., Senators Alsobrooks and Wyden highlighted the dangers of allowing individuals to bet on the outcomes of clinical trials and drug approvals. They argue that such markets could undermine scientific integrity, create harmful incentives for researchers, and negatively influence trial participants' decisions.
The senators are particularly worried about insider trading risks, given that researchers and regulators may have access to confidential information. They have requested HHS to disclose all internal communications regarding staff involvement in these prediction markets, as well as any correspondence with market platforms and regulatory bodies.
Kalshi and Polymarket are the primary platforms offering these contracts, with Kalshi implementing measures to mitigate risks, such as limiting markets to late-stage trials and ensuring participant verification.
The senators emphasized the need for HHS, FDA, and NIH to maintain public trust in the drug development process by establishing safeguards against profiting from drug success and approval outcomes